ストックスクリーナーアプリを入手
7.46
5.33%
-0.42
前日終値:
$7.88
開ける：
$7.865
24時間の取引高:
52,711
Relative Volume:
0.72
時価総額：
$80.60M
収益：
$123.24M
当期純損益:
$136.00K
株価収益率:
-373.00
EPS:
-0.02
ネットキャッシュフロー:
$-148.99M
1週間 パフォーマンス:
-12.75%
1か月 パフォーマンス:
-36.83%
6か月 パフォーマンス:
-36.80%
1年 パフォーマンス:
-61.35%
1日の値動き範囲:
$7.31
$7.875
1週間の範囲:
$6.64
$8.8927
52週間の値動き範囲:
$6.64
$30.60
Seres Therapeutics Inc Stock (MCRB) Company Profile
名前
Seres Therapeutics Inc
セクター
電話
617 945 9626
住所
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
7.48 | 80.60M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.89 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.22 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
540.50 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
265.37 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.31 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-08 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-21 | 開始されました | JP Morgan | Neutral |
| 2021-07-23 | ダウングレード | Goldman | Neutral → Sell |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-03-05 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-11 | アップグレード | Jefferies | Hold → Buy |
| 2019-04-30 | 開始されました | Jefferies | Hold |
| 2018-10-22 | 開始されました | Chardan Capital Markets | Buy |
| 2017-10-13 | 開始されました | Oppenheimer | Outperform |
| 2017-08-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-01 | 繰り返されました | FBR & Co. | Outperform |
| 2016-08-12 | 繰り返されました | FBR Capital | Outperform |
| 2016-08-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-07-29 | 再開されました | H.C. Wainwright | Buy |
| 2016-03-30 | 開始されました | FBR Capital | Outperform |
| 2016-03-03 | 開始されました | Guggenheim | Buy |
| 2016-01-25 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-22 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-07-21 | 開始されました | Goldman | Neutral |
| 2015-07-21 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Seres Therapeutics Inc (MCRB) 最新ニュース
Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com
Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - Defense World
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus
Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks
Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus
Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World
Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
5 Best Microbiome Companies (May 2025) - Securities.io
Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World
Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan
Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World
MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News
Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan
Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com India
Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com
JP Morgan downgrades Seres Therapeutics Inc (MCRB) rating to an Underweight - knoxdaily.com
Oppenheimer Adjusts Seres Therapeutics Price Target to $5 From $9, Maintains Outperform Rating - marketscreener.com
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 - marketscreener.com
Upcoming Stock Splits This Week (April 21 to April 25) – Stay Invested - The Globe and Mail
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts
MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa
MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com
Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com
Seres Therapeutics Inc (MCRB) 財務データ
収益
当期純利益
現金流量
EPS
4.19%
0.27%
大文字化:
|
ボリューム (24 時間):